^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HBM1047

    i
    Other names: HBM1047
    Associations

    News

    Trials
    Company:
    Harbour BioMed
    Drug class:
    CD200R1 antagonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    HBM1047, a novel fully human anti-CD200R1 antagonist antibody with potent anti-tumor efficacy in preclinical model (SITC 2022)
    In addition, HBM1047 had a favorable PK profile in mice and exhibited good developability properties. Conclusions In conclusion, HBM1047 represents a novel fully human anti-CD200R1 antagonistic antibody with promising therapeutic potential for the treatment of cancer.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD200 (CD200 Molecule)
    |
    CD200 expression
    |
    HBM1047